In Proclarix, Proteomedix has developed a blood test that can reliably diagnose prostate cancer. This should decrease the number of biopsies in patients with suspected prostate cancer, which are expensive and psychologically stressful for the patient. According to a press release from the company, the product has now been launched in Europe.
Proteomedix writes in the press release that the launch follows extensive tests proving that Proclarix is more accurate than other in-vitro methods for the detection of prostate cancer. This means that Proclarix has the potential to significantly decrease the number of necessary biopsies.
Helge Lubenow, CEO of Proteomedix is cited in the press release: “We are very excited to be able to start the commercialization of Proclarix. I would like to thank the team and our clinical partners for their commitment and hard work to make this happen.”
Proteomedix is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) with headquarters in Schlieren.